According to a release issued by Suven to the BSE today, the medicine is expected to be useful in the treatment of CNS
disorders like Alzhimer's disease and Attention Deficit Hyperactivity Disorder.
This is the fourth European patent for Suven.
Top Section
Explore Business Standard